At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 261 enrolled
Drug / intervention
Netarsudil Ophthalmic Solution 0.02%drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-label Study of Rhopressa® (Netarsudil Ophthalmic Solution) 0.02% for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting
In Brief
A Phase 4 clinical trial evaluating Netarsudil Ophthalmic Solution 0.02% for Glaucoma, Open-Angle and Ocular Hypertension. Completed, enrolled 261 participants across 22 sites.
Detailed Summary
To evaluate the IOP lowering efficacy of netarsudil ophthalmic solution 0.02% when used as monotherapy or when used concomitantly with other IOP-lowering agents in subjects with elevated IOP due to open angle glaucoma or ocular hypertension in a real-world clinical setting. The study is an open-label design. The patients will receive treatment for 12 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Open-Angle, Ocular Hypertension
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20192020202120222023202420252026
Enrollment StartDec 2018
First PostedJan 2019
Primary CompletionJul 2019
TodayJul 2026
First PostedJan 17, 2019
Enrollment StartDec 27, 2018
Primary CompletionJul 26, 2019
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 7.5 years ago
Interventions
Netarsudil Ophthalmic Solution 0.02%drug
1 drop in each eye once daily in the evening